Syncona Limited

BACT

GG00B8P59C08

Investment Holding Companies

Market Closed - London S.E. Other stock markets 11:35:28 2024-09-19 am EDT			5-day change	1st Jan Change
112.00 ^GBX	-0.18%		-3.11%	-9.24%

03:12pm	Syncona notes investee Achilles' plan to close its lead program	AN
Aug. 13	Syncona net asset value down 5% reflecting fall in Autolus share price	AN

Syncona Adds Ionctura And Yellowstone Biosciences To Its Portfolio

June 20, 2024 at 02:04 am EDT

June 20 (Reuters) - Syncona Ltd:

* SYNCONA: ADDED TWO NEW COMPANIES TO PORTFOLIO, IONCTURA AND YELLOWSTONE BIOSCIENCES Source text for Eikon: Further company coverage:

Latest news about Syncona Limited

Syncona notes investee Achilles' plan to close its lead program	09:12am	AN
Syncona net asset value down 5% reflecting fall in Autolus share price	Aug. 13	AN
Syncona Logs Decline in Fiscal Q1 Net Asset Value	Aug. 13	MT
Thor Energy drilling starts; Deltic accepts licence	Jul. 08	AN
Syncona Invests Additional $42.5 Million in Beacon Therapeutics	Jul. 03	MT
Syncona's portfolio Beacon Therapeutics raises USD170 million	Jul. 03	AN
Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors	Jul. 02	CI
Syncona Chair & CEO Hollowood buys GBP100,000 in shares	Jun. 25	AN
Syncona Invests in Two Oncology Companies	Jun. 20	MT
Syncona swings to annual profit despite challenging market conditions	Jun. 20	AN
Syncona Limited, 2024 Earnings Call, Jun 20, 2024	Jun. 20
Syncona Posts Swings to Profit for FY24; Total Investment Income Rises	Jun. 20	MT
Syncona Adds Ionctura And Yellowstone Biosciences To Its Portfolio	Jun. 20	RE
Tranche Update on Syncona Limited's Equity Buyback Plan announced on September 29, 2023.	Jun. 20	CI
Syncona Limited Reports Earnings Results for the Full Year Ended March 31, 2024	Jun. 19	CI
Syncona’s Freeline, SwanBio Combine to Form Spur Therapeutics	Jun. 17	MT
Syncona to invest GBP40 million into newly created Spur Therapeutics	Jun. 17	AN
Syncona notes Autolus's first quarter loss widens amid higher costs	May. 17	AN
Syncona's Freeline gets positive results for Gaucher disease	May. 09	AN
Jefferies cuts AJ Bell; Deutsche likes ConvaTec	May. 03	AN
Syncona agrees to sell stake in investee company for GBP7.4 million	Apr. 11	AN
Syncona to Sell Stake in Portfolio Company to Century Therapeutics	Apr. 11	MT
Syncona notes investee Achilles's annual loss narrows	Apr. 04	AN
Syncona portfolio company Autolus posts widened loss for 2023	Mar. 14	AN
Syncona’s Takeover of Freeline Therapeutics Becomes Effective	Feb. 20	MT

Syncona Limited is a Guernsey-based closed-ended investment company. The Companyâs investment objective is to achieve superior long-term capital appreciation from its investments. It seeks to achieve returns over the long term. It focuses on creating, building and scaling companies around science to create a diversified portfolio of 20-25 global healthcare businesses, across development stage and therapeutic areas. It focuses on developing treatments for patients by working in close partnership with academic founders and management teams. The Company makes its life science investments through Syncona Holdings Limited, a subsidiary of the Company. It maintains its capital pool through Syncona Investments LP Incorporated (the Partnership) in which the Company is the sole limited partner. The general partner of the Partnership is Syncona GP Limited (the General Partner), a wholly owned subsidiary of the Company. Syncona Investment Management Limited is its alternative investment manager.

Employees

1,050

Sector

Investment Holding Companies

Calendar

2024-11-14 - Q2 2025 Earnings Release

More about the company